Sources

1 Sleisinger and Fordtrans ed. Gastrointestinal and Liver Disease, Philadelphia: WB Saunders Company, 1998; 1749-51.

2 Wilson, Jean D. ed. Harrison's Principals of Internal Medicine, 12th ed. Volume 2. New York: McGraw-Hill, Inc., 1991; 1641-2.

3 Hanaurer et al. "The definition, diagnosis and treatment of moderate ulcerative colitis." Proceedings of a roundtable. University of Chicago Pritzker School of Medicine Center for Continuing Medical Education and IMED Communications: 2005.

4 Kornbluth A., Sachar, D. Ulcerative colitis practice guidelines in adults (update). American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol 2004; 99, 1371-1385.

5 Stein S, Rood R. Inflammatory Bowel Disease, a Guide for Patients and their Families. Philadelphia, PA: Lippincott-Raven; 1999:31.

6 Miner, Philip B. "Clinical Features, Course, Laboratory Findings, and Complications in Ulcerative Colitis." Inflammatory Bowel Disease: Fifth Edition. ed. Joseph B. Kirsner. Chicago: W.B. Saunders Company, 2000. pg. 301.

7 Lichtman, Steven N. and Sartor, R. Balfour. "Extraintestinal Manifestations of Inflammatory Bowel Disease; Clinical Aspects and Natural History. Inflammatory Bowel Disease From Bench to Bedside, Ed. Targan, Stephan R. and Fergus Shanahan. Baltimore: Williams & Wilkins. 1994. 326.

8 Levine, Joel B. "Extraintestinal Manifestations of Inflammatory Bowel Disease." Inflammatory Bowel Disease, 5th Edition. Ed. Kirsner, Joseph B. Philadelphia: W.B. Saunders Co., 2000; 401-402.

9 CCFA. "Bringing light to the risk of colorectal cancer among Crohn's and ulcerative colitis patients. Available at: http://www.ccfa.org/frameviewer/?url=/media/pdf/crcbrochure06.pdf. Accessed April 16, 2007.

10 Ahnen, DJ. Gastrointestinal malignancies in inflammatory bowel disease. In: Kirsner, JB, ed. Inflammatory Bowel Disease. 5th ed. Chicago, Il: W.B. Saunders Company; 2000:382.

11 American Cancer Society. "What Causes Colorectal Cancer?" Available at: http://www.CCFA.org/docroot/CRI/content/CRI_2_2_2X_What_Causes_Colorectal_Cancer.asp?sitearea. Accessed April 16, 2007.

12 Lee, D. "Colon Cancer". MedicineNEt.com. Available at: http://www.medicinenet.com/colon_cancer/article.htm. Accessed April 16, 2007.

13 Glickman, Robert M. "Inflammatory Bowel Disease: Ulcerative colitis and Crohn's disease." Harrison's Principles of Internal Medicine. Ed. Wilson, Jean D. et al. 12th ed. Volume 2. New York: McGraw-Hill, Inc., 1991. 1269.

14 Saibil, Fred MD. Crohn's Disease & Ulcerative Colitis: Everything You Need to Know. New York: Firefly Books, 1997; 9-10.

15 Yang, Huiying, and Jerome I. Rotter. "Genetics of Inflammatory Bowel Disease." Inflammatory Bowel Disease: From Bench to Bedside. Ed. Targan, Stephan R. et al. Baltimore, MD: Williams & Wilkins. 1994; 32-35, 55.

16 Yang, Huiying, and Jerome I. Rotter. "The Genetics of Ulcerative Colitis and Crohn's Disease." Inflammatory Bowel Disease: Fifth Edition. ed. Joseph B. Kirsner. Chicago: W.B. Saunders Company, 2000; pp. 250-252.

17 Enrollment Survey, April 1998 - February 2000.

18 Margolis, Simeon and Hamilton Moses III. The Johns Hopkins Medical Handbook. New York: Rebus, distributed by Random House, 1992.196.

19 Mower G. et. al., Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 1995; 7: 853-858.

20 Hanan, Ira M. "Fertility and Pregnancy in Inflammatory Bowel Disease." Inflammatory Bowel Disease From Bench to Bedside, Ed. Targan, Stephan R. and Fergus Shanahan. Baltimore: Williams & Wilkins. 1994. 695.

21 Hanauer, Stephen B. and Kane, Sunanda V. "The Pharmacology of Anti-Inflammatory Drugs in Inflammatory Bowel Disease." Inflammatory Bowel Disease, 5th Edition. Ed. Kirsner, Joseph B. Philadelphia: W.B. Saunders Co., 2000; 513.

22 Willoughby C. P., Truelove S. C. "Ulcerative Colitis and pregnancy" GUT. 1980; 21: 469-474.

23 Beers MH, Porter RS et al, eds. The Merck Manual of Diagnosis and Therapy. 18th ed. Whitehouse station, NJ: Merck Research Laboratories: 2006:Chapter 302. Available at: http://www.merck.com/mmpe/sec20/ch302/ch302b.html. Accessed April 16, 2007.

24 American Demographics, Jan 1993

25 The Intimate Relationship of Sex and IBD, Foundation Focus, Summer, 1998.

26 Scrimshaw, N.S., and Murray, E.B. "The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance." American Journal of Clinical Nutrition. 1988; 48:1083-1159.

27 This information is an estimate derived from the use of information under license from IMS National Prescription data for the 12-month period ending February 2007. IMS expressly reserves all rights, including rights of copying, distribution, and republication.

28 IMS National Prescription data, 1992-July 2006.


Asacol (mesalamine) delayed-release tablets, available only by prescription, are indicated to treat mild to moderate flare-ups of ulcerative colitis and maintain remission of ulcerative colitis. Asacol is generally well tolerated. In studies of flare-ups, some people taking Asacol reported headache, abdominal pain, general pain, rash, upset stomach, and worsening of colitis symptoms. In a six month maintenance study, some people reported headache, runny nose, general pain, sore throat, infection, and nervousness. You should not take Asacol if you are allergic to Asacol or to salicylates such as aspirin. Tell your doctor if you have kidney problems or a history of kidney disease. It is recommended that all people have their kidney function tested prior to starting Asacol tablets and periodically while on Asacol therapy. Serious side effects may occur. If you have questions about taking Asacol, please talk to your doctor.

This information was printed from Asacol.com.
Visit Asacol.com to get more information on Ulcerative Colitis.
Asacol is a registered trademark of Medeva Pharma Suisse AG, used under license by Procter & Gamble Pharmaceuticals, Inc.

Privacy BBB OnLine